Dear Christoph,

 

Thanks for your response.

 

On 1: I understand your hesitation to go further, I am just thinking about what will make the report most useful in terms of our media work, as – without any new cases / hearings – this is our only chance to make some public pressure in the coming months. For our work at Arche Noah I would find it very useful to have some bolder predictions and statements, but it is ultimately for you to determine what is plausible.  

 

On 2: To clarify: I understand from the analysis that companies are putting claims related to conventional breeding and GE processes in their applications, even when in reality they just used conventional methods, to make it all sounds very technical so they get the patent on the trait. But where I am not so clear is how we make a clear, understandable link between this analysis and the “random mutagenesis” loophole. This might be more of an issue for our media work than for the report itself.

 

Thanks

Katherine

 

Von: Npos_2018 [mailto:npos_2018-bounces@testbiotech.de] Im Auftrag von Christoph Then
Gesendet: Dienstag, 9. Februar 2021 16:52
An: npos_2018@testbiotech.de
Betreff: Re: [Npos_2018] dicussion on first draft of the new report (feedback until 12 February)

 

Dear Katherine

 

thanks for the feedback.

 

before others jump on the same train, some quick explanations:

 

these just some thoughts on your comments, maybe useful to move ahead.

 

Cheers

Christoph

 

 

 

Am 09.02.21 um 16:34 schrieb ARCHE NOAH Katherine Dolan:

Dear Christoph,

 

Thanks for the draft, which is very interesting. It is great we can include so much new context - thanks to everyone involved.

 

Attached are my comments. My main feedback:

 

·        We should do more to underline the consequences of waiting to see what happens with these applications, as the governments currently want to do. Could we add in the numbers of relevant applications from H2 2012, 2018-19 to give a total number of patents applications that could already slip through the loopholes owing to inaction? And do some extrapolation into the future? Perhaps for the media work we could think about a theme like a ticking time bomb or a trawler fishing up diversity while politicians do nothing.

·        It would be helpful to explain in a bit more detail the new strategy of the companies. I suspect this is more obvious to you than the average reader. Based on our arguments about the legal loopholes, you would logically expect that most applications would include random mutagenesis, but this is not the case.

·        In terms of structure, I would propose to move the analysis of the 2020 applications more to the front (as this is what is new and report-wothy) and move the legal analysis to the end (and potentially shorten it, where we repeat our demands).

 

Best,

Katherine

 

 

-----Ursprüngliche Nachricht-----
Von: Npos_2018 [mailto:npos_2018-bounces@testbiotech.de] Im Auftrag von Johanna Eckhardt no-patents-seeds.org
Gesendet: Dienstag, 9. Februar 2021 16:05
An: npos_2018@testbiotech.de
Betreff: [Npos_2018] IMPORTANT first draft of the new report (feedback until 12 February)

 

Dear all,

 

as mentioned in today's conference call, could you please come back to us with your feedback on the report until the end of the week (12 February)?

We can then continue with edits and the translation into German.

 

Thank you!

 

Best,

Johanna

 

Johanna ECKHARDT

Project Coordination

Tel. +43 680 21 26 343

johanna.eckhardt@no-patents-on-seeds.org

 

NO PATENTS ON SEEDS!

www.no-patents-on-seeds.org

www.facebook.com/nopatentsonseeds

www.twitter.com/nopatentsonseed

 

 

 

-----Original Message-----

From: Npos_2018 [mailto:npos_2018-bounces@testbiotech.de] On Behalf Of Christoph Then

Sent: Monday, February 8, 2021 9:18 AM

To: npos_2018@testbiotech.de

Subject: [Npos_2018] first draft of the new report (docx version)

 

dear all

 

 

please see attached the first draft of the new report.

 

It uses lots of parts from the previous one. However it follows another

logic: The focus now is on the loopholes, while last time we did not know the outcome of G3/19 and therefore had to take a wider approach.

 

more recent figures from overall patent applications and pinto will be added.

 

I especially like figure 3 which repeats what we are saying about the differences between GE and random mutagenesis, and was produced with public money to educate public on advantages of New GE.... I will try to organise a slightly adopted version.

 

I can give a short introduction in the zoom meeting we have today and tomorrow.

 

 

cheers

 

Christoph

 

 



_______________________________________________
Npos_2018 mailing list
Npos_2018@testbiotech.de
https://lists.testbiotech.de/cgi-bin/mailman/listinfo/npos_2018